Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharmaceutics

This article was originally published in The Tan Sheet

Executive Summary

FDA approves process validation for five of the company's OTC drugs -- acetaminophen 500 mg tabs and caplets, children's acetaminophen fruit-flavored 80 mg tabs, children's acetaminophen grape-flavored 80 mg tabs, and dimenhydrinate 50 mg tabs -- Biopharmaceutics reported Oct. 7. In a Sept. 28 letter, FDA told the firm, however, that the agency "will need to verify by inspection that the deviations have been corrected and that Biopharmaceutics is in compliance" with GMPs. The company's operations were shut down in November 1991 when FDA won a temporary restraining order. The firm subsequently committed to correcting GMP problems in a consent agreement with FDA ("The Tan Sheet" Aug. 2, p. 17). The company plans to continue its validation program for an additional 15-20 OTC products.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS081994

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel